3 results
The primary objective is:* To determine the overall response rate (ORR) of 4 weekly infusions of obinutuzumab monotherapy (Induction I) in patients with rituximab-refractory follicular lymphoma.The secondary objectives are:* To determine the…
Primary objectives:* Part 1: To evaluate the safety and tolerability and determine the recommended dose(s) of INCB059872 for further study in advancedmalignancies.* Part 2: To further evaluate the safety and tolerability of INCB059872 for further…
The primary objective of this study is to investigate the potential differential effects of RTX and OBI on the composition of lymph nodes and other target organs (i.e. skin and/or kidney) as well as (subsets of) immune cells in the peripheral blood…